Deciphera Pharmaceuticals (DCPH) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices rise 2% as US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
August 4, 2022 7:00 AM EDTSecond Quarter 2022 Total Revenue of $32.5 Million; QINLOCK® Net Product Revenue Increases 43% to $31.5 Million Compared to Second Quarter 2021
Phase 1 Single Agent Dose Escalation Data for DCC-3116 Selected for Oral Presentation as a Proffered Paper at the ESMO Congress 2022 in September
Updated Phase 1/2 Results for Study of Vimseltinib in TGCT Patients Selected for Poster Presentation at the ESMO Congress 2022; Continued Patient Enrollment in the Pivotal Phase 3 MOTION Study
Nomination of New Development Candidate from Pan-RAF Research Program Expected by Fourth Quarter 2022
WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera... More
